TERN - Company ID 0001831363
The table below shows Terns Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A |
Terns Pharmaceuticals, Inc. reported annual revenue of $0.00 for fiscal year 2022. That is down 100.0% from $1.00M in fiscal 2021. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $7.80M |
| $7.03M |
| $8.71M |
| $9.77M |
| $7.18M |
| $6.86M |
| Operating income | -$27.72M | -$27.38M | -$27.43M | -$24.94M | -$25.54M | -$25.45M |
| Income tax | $46.00K | $64.00K | $88.00K | $62.00K | $61.00K | $97.00K |
| Net income | -$24.64M | -$24.09M | -$23.91M | -$21.95M | -$22.74M | -$22.37M |
| EPS (diluted) | -$0.27 | -$0.26 | -$0.26 | -$0.28 | -$0.31 | -$0.30 |